ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

ISTH 2022 Congress

July 9-13, 2022. London, England, UK.

View by Title View by Number View Themes
Jump to:  View All • a b c d e f g [h] i j k l m n o p q r s t u v w x y z
  • Abstract Number: OC 20.5

    Haemophilia-mediated bleeding induces red pulp macrophage expansion

    H. Hawerkamp1, A. Yeow1, C. Byrne1, A. Chevalier1, L. Matarazzo1, J. O'Sullivan2, V. Kelly3, B. Gangadharan4, B. Reipert4, J. O'Donnell5, P. Turecek6, P. Fallon7

  • Abstract Number: OC 78.4

    Haemorrhagic sub-phenotypes in hereditary haemorrhagic telangiectasia are associated with high impact DNA variants in platelet/coagulation genes responsible for general population bleeding disorders

    K. Joyce1, E. Onabanjo2, S. Brownlow2, F. Nur2, K. Olupona2, K. Fakayode2, M. Sroya3, G. Thomas3, T. Ferguson2, J. Redhead2, C. Millar2, N. Cooper3, M. Layton3, F. Boardman-Pretty4, M. Caulfield4, G. Research Consortium4, C. Shovlin3

  • Abstract Number: PB0086

    Haemostatic differences between SARS-CoV-2 PCR-positive and -negative patients at the time of hospital admission

    J. Remijn1, M. Traets2, R. de Laat-Kremers3, S. Verweij2, M. Ninivaggi4, E. Jong2, D. Huskens5, B. Blok2, G. Remme2, A. Miszta3, R. Nijhuis6, J. Herder7, R. Fijnheer2, M. Roest4, A. Fiolet2, B. de Laat8

  • Abstract Number: PB1333

    Hand grip strength and risk of incident venous thromboembolism: The Tromsø Study

    O. Leknessund1, V. Morelli2, B. Strand3, J. Hansen4, S. Brækkan4

  • Abstract Number: VPB0722

    Health education needs in hematological orphan diseases for professionals, sick people and caregivers in Ibagué, Tolima

    N. PERDOMO OLARTE

  • Abstract Number: PB1327

    Health-Related Quality of Life and physical capacity in patients with residual perfusion defects after pulmonary embolism

    Ø. Jervan1, S. Parker2, J. Gleditsch3, D. Rashid3, W. Ghanima4

  • Abstract Number: PB0651

    Health-Related Quality-of-Lives in Hemophilia A patients on prophylactic therapy of Emicizumab (Hemlibra)

    M. Borhany1, M. Abid1, S. Zafar1, R. Ahmed2, A. Jamal2, R. Nadeem2

  • Abstract Number: PB1387

    Heavy menstrual bleeding from anticoagulation therapy significantly impacts on women’s quality of life – findings from the PERIOD programme of work

    J. Patel1, O. Nzelu2, L. Roberts3, J. Johns2, J. Ross2, R. Arya4

  • Abstract Number: VPB0760

    Heightened Procoagulation After Thromboprophylaxis Completion inOrthopaedic Surgery Patients with Metastatic Bone Disease: Outcome of A Pilot Study

    E. Agbani1, L. Yamaura2, D. Young2, M. Monument2, L. Skeith2, A. Dufour2, P. Schneider2

  • Abstract Number: PB0077

    Hematologic Findings and Complications of SARS-COV-2 in Children and Young Adults

    R. Graham1, D. Kaur2, C. Neunert3, Z. Jin4, P. Satwani5

  • Abstract Number: VPB0723

    Hematological orphan diseases and health literacy in sick people: State of the art

    N. PERDOMO OLARTE

  • Abstract Number: VPB0250

    Heme regulates inflammatory signaling pathways in human choroid plexus epithelial cells after preterm intraventricular hemorrhage

    Z. Fejes1, M. Pócsi2, Á. Gyetvai2, S. Póliska2, A. Tóth2, E. Balogh2, Á. Rusznyák2, F. Fenyvesi2, V. Jeney2, J. Kappelmayer2, B. Nagy2

  • Abstract Number: PB0704

    Hemizygous FGG p.Ala108Gly in a hypofibrinogenemic patient with a heterozygous 14.8 Mb deletion encompassing the entire fibrinogen gene cluster

    A. Couzens1, A. Lebreton2, F. Masclaux3, M. Guipponi3, C. Pebrel-Richard4, F. Laffargue5, P. Gembara2, A. Casini6, M. Neerman-Arbez7

  • Abstract Number: VPB0835

    Hemoglobin concentration is a determinate of plasma VWF and FVIII levels

    M. Carter-Febres, C. Tarango, E. Mullins

  • Abstract Number: PB0663

    Hemophilia Joint Health Score (HJHS) and Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) score in patients with hemophilia: experience from a single comprehensive care center

    R. Gualtierotti1, A. Truma2, V. Begnozzi3, E. Biguzzi3, S. Siboni4, S. Arcudi5, A. Ciavarella6, E. Boccalandro3, F. Peyvandi7

  • Abstract Number: PB1135

    Hemophilia Registry in a province in nothern Spain

    P. Lopez1, I. Hernández De Castro2, A. Porro1, J. Iglesias1, G. Florez Meana3, C. Rodriguez de Miñon3, D. Martinez Carballeira3, J. Corte Buelga3, A. Bernardo1, D. Mateos Jimenez3, I. Soto1

  • Abstract Number: OC 16.2

    Hemorrhage risk in direct oral anticoagulant users receiving tamoxifen for breast cancer versus aromatase inhibitors: The STOP-Bleed Cancer study

    T. Wang1, A. Clarke2, A. Awan1, M. Carrier1, M. Sood1

  • Abstract Number: PB0323

    Hemorrhagic clinic in an immune-mediated and prothrombotic entity: heparin-induced thrombocytopenia (HIT). Case report

    I. Hernández De Castro1, A. Bernardo2, J. Iglesias2, P. Lopez2, A. Porro2, I. Soto2

  • Abstract Number: LB 02.2

    Hemorrhagic, Coagulopathic, and Thrombotic (HECTOR) Complications Among Critically-Ill Patients with COVID-19: An International COVID-19 Critical Care Consortium Study

    J. Fanning1, R. Fanning2, N. Weaver3, M. Griffee4, S. Cho1, M. Panigada5, A. Zaaqoq6, N. White7, N. Obonyo8, A. Labib9, Y. Chia10, B. Fan11, R. Arora12, D. Chiumello13, A. Torres14, J. Suen15, G. Li Bassi15, G. Peek16, J. Fraser15, H. Dalton17

  • Abstract Number: PB1275

    Hemostasis after vessel injury occurs under high shear conditions

    A. YAKUSHEVA1, K. Butov2, G. Bykov3, G. Závodszky4, F. Ataullakhanov3, M. Panteleev3, P. Mangin5

  • Abstract Number: PB1023

    Hemostasis in Yellow Fever: results from the 2018 outbreak in Brazil

    L. Jardim1, M. Brandão Franco1, B. Carvalho2, F. Basques2, D. RIbeiro3, L. Gallo4, S. Rezende5

  • Abstract Number: VPB0107

    Hemostasis markers determining unfavorable outcome in covid-induced coagulopathy

    I. Berger1, A. Makhmudova2, M. Shamsutdinova3, A. Achilova2, O. Madasheva2

  • Abstract Number: PB0808

    Hemostatic response to exercise training in patients with continuous-flow left ventricular assist device

    C. Chan1, M. Passmore2, O. Tronstad3, H. Seale3, M. Bouquet2, A. Hogan4, N. Sowden4, D. Platts4, W. Chan4, A. Dashwood4, D. McGiffin5, A. Maiorana6, J. Suen2, J. Fraser2, B. Meyns7, L. Fresiello7, S. Jacobs7

  • Abstract Number: PB0819

    Hemostatic Response to Subcutaneous versus Intranasal Desmopressin in Patients with Von Willebrand Disease (VWD)

    S. Saey1, A. Sharathkumar2, W. Karla3, M. Krantz3, A. Currie3, U. Perepu3, M. Shinkle3

  • Abstract Number: OC 21.2

    Hemostatic results for up to 6 years following treatment with valoctocogene roxaparvovec, an AAV5-hFVIII-SQ gene therapy for severe hemophilia A

    M. Laffan1, S. Rangarajan2, W. Lester3, E. Symington4, B. Madan5, D. Hart6, M. Li7, T. Robinson8, G. Pierce9, W. Wong7

  • Abstract Number: PB0377

    Heparin and heparin proteoglycan-mimetics activate platelets via PEAR1 and PI3Kbeta

    C. Kardeby1, A. Evans1, J. Campos1, C. Smith1, A. Slater1, E. Martin1, S. Severin2, A. Brill1, G. Pejler3, Y. Sun1, S. Watson4

  • Abstract Number: PB0034

    Heparin Induced Thrombocytopenia Before and During COVID-19 Pandemia in Iran

    M. Ahmadinejad1, M. Shahbazi1, A. Teimourpour1, M. Mojtabavi Naeini2, B. Asadi1, A. Rajabi3, M. Javan1, P. Eshghi

  • Abstract Number: VPB1119

    Heparin monitoring during ECMO: Anti-Xa assay with and without dextran

    E. Hammami, L. Stiel, A. Debliquis, B. Drénou, i. Harzallah

  • Abstract Number: PB0325

    Heparin-induced thrombocytopenia (HIT) in a COVID-19 patient on extracorporeal membrane oxygenation (ECMO) support: case report experience with rivaroxaban

    V. Privitera1, M. Garbarini2, D. Mezzarobba3, F. Chuliber4, M. Lopez5, D. Penchasky3, M. Villagra Iturre3, E. Viñuales3, J. Arbelbide3, M. Martinuzzo6

  • Abstract Number: PB0782

    Hepsin is a risk factor for thrombosis and metastasis in localized colorectal cancer patients

    D. Zaragoza Huesca1, A. Nieto Olivares2, F. García Molina3, G. Ricote Sánchez4, M. Sánchez Cánovas5, A. Martínez2, P. Garrido-Rodríguez6, J. Peñas-Martínez4, S. Montenegro Luis4, V. Vicente6, A. Carmona Bayonas7, I. Martínez Martínez8

  • Abstract Number: VPB0720

    Hereditary Severe Factor XIII Deficiency in Northern region of Turkey

    C. Albayrak1, D. Albayrak2

  • Abstract Number: PB1232

    Hermansky-Pudlak syndrome: Identification of novel variants in the genes HPS3, HPS5, and DTNBP1 (HPS-7) and analysis of lymphocyte cytotoxicity for the HPS-7 patient

    D. Boeckelmann1, M. Wolter2, K. Neubauer2, L. Weiss3, H. Schulze4, F. Sobotta2, A. Lenz2, H. Glonnegger2, B. Käsmann-Kellner5, J. Mann6, S. Ehl6, B. Zieger2

  • Abstract Number: PB1247

    High bleeding rates in delta-storage pool disease

    E. Van Heerwaarde1, R. Schutgens2, A. Huisman1, I. Kremer Hovinga3

  • Abstract Number: PO0063

    High factor VIII levels and recurrent thromboembolism in patients with and without inflammatory bowel disease: a retrospective comparative study

    S. Schulman, G. Eagle

  • Abstract Number: VPB1222

    High Frequency of Bone Marrow Evaluations but Low Diagnostic Yield in Relapsed or Refractory Immune Thrombocytopenia

    K. Taparia, E. Wall, H. Sun

  • Abstract Number: PB0770

    High levels of TLT-1+, but not Gp1b+, Microparticles Are Indicative of Poor Outcomes in Acute Respiratory Distress Syndrome

    A. Gibson1, A. Washington2, J. Warrick1

  • Abstract Number: PB0075

    High plasma levels of activated factor VII-antithrombin complex indicate increased tissue factor expression/activation in patients with COVID-19.

    N. Martinelli1, N. Osti1, A. Rigoni2, S. De Marchi1, M. Montagnana1, A. Castagna1, P. Pattini1, S. Udali1, L. De Franceschi1, E. Tinazzi1, L. Delfino1, G. Sartori1, A. Azzini1, E. Tacconelli1, P. Van Dreden3, G. Lippi1, D. Girelli1, O. Olivieri1, S. Friso1, F. Pizzolo1

  • Abstract Number: OC 44.4

    High plasma levels of C1 esterase inhibitor reduce intrinsic pathway-initiated coagulation and are associated with reduced future risk of venous thromboembolism

    S. Grover1, O. Snir2, K. Hindberg2, T. Englebert1, S. Brækkan3, Z. Pólai4, V. Morelli5, H. Farkas4, S. Jensen2, A. Wolberg1, T. Mollnes6, T. Ueland6, N. Mackman1, J. Hansen3

  • Abstract Number: PB0178

    High plasma levels of IgG4 anti-FVIII is the hallmark of immune tolerance failure in patients with hereditary hemophilia A: results from the BrazIT Study

    D. Chaves1, R. Camelo2, B. Ayala3, L. Etto4, A. De Oliveira5, V. Franco6, M. Roberti7, M. De Cerqueira8, R. Ribeiro9, F. Callado10, T. Anegawa11, M. Cerqueira12, S. Rezende3

  • Abstract Number: PB0017

    High prevalence and wide variety of clonal haematopoiesis-driver mutations in patients with severe aortic valve stenosis undergoing transcatheter aortic valve replacement

    F. Lassalle1, N. Duployez2, F. Vincent1, A. Rauch1, M. Rosa1, B. Staels1, C. Preudhomme2, S. Susen3, E. Van Belle1, A. Dupont1

  • Abstract Number: PB0095

    High Prevalence of Anti-PF4 Antibodies Among Hospitalized Pediatric COVID-19 Patients and The Impact on Morbidity and Mortality

    S. Hui1, S. Sartain2, K. Bruzdoski3, V. Kostousov1, A. Navaei1, L. Hensch1, J. Teruya1

  • Abstract Number: VPB1428

    High Prevalence of Non RhD Antibodies Among Antenatal Women attending Tertiary care Centre Hyderabad Pakistan

    A. SULTANA1, I. UJJAN2

  • Abstract Number: OC 08.1

    High rate of recurrent thrombosis in children with unprovoked venous thromboembolism

    H. Whitworth1, R. Hubbard2, C. Leonard2, C. Witmer3, L. Raffini1

  • Abstract Number: OC 44.5

    High α2-macroglobulin levels are a risk factor for cardiovascular events

    R. de Laat-Kremers1, S. Constanzo2, Q. Yan3, A. Di Castelnuovo4, A. De Curtis2, C. Cerletti2, M. Donati2, B. de Laat5, L. Iacoviello2

  • Abstract Number: PB0849

    High-Throughput Screening to Identify Novel Small-Molecule Inhibitors of Clot Retraction

    c. buitrago1, M. Menezes2, F. Glickman3, B. Coller2

  • Abstract Number: VPB1347

    Higher In-hospital Mortality of Cancer-Associated Pulmonary Embolism: Findings from the CURES Registry

    J. Liu1, Z. Zhang2, P. Yang3, Z. Zhai2

  • Abstract Number: OC 41.3

    Histidine-rich glycoprotein binds GPIIb/IIIa and attenuates platelet aggregation

    R. Malik1, M. Neves2, J. Zhou1, R. Hussain1, J. Fredenburgh3, H. Ni4, J. Weitz1

  • Abstract Number: PB0873

    Histology of Shear-Induced Platelet Aggregated (SIPA) Thrombus Formed in vitro

    D. Ku1, D. Kim2

  • Abstract Number: PB1040

    Histone-3 plasma levels as a potential pre-thrombotic marker up regulated in patients with digestive carcinomatosis

    S. Mirshahi1, I. aldybiat2, M. Ullah2, G. Contant1, J. Soria2, M. Pocard2, M. Mirshahi3

  • Abstract Number: OC 78.3

    HMB-001 – a novel bispecific antibody accumulating and targeting endogenous FVIIa to activated platelets for subcutaneous prophylaxis in multiple bleeding disorders including Glanzmann Thrombasthenia

    H. Ostergaard1, M. Zivkovic2, P. Gandhi1, M. Kjelgaard-Hansen3, M. Broberg3, T. Elm3, M. Stougaard Kyhn3, M. Løvgreen3, E. Olsen1, C. Rea4, B. Sorensen5, S. Bjorn1, R. Schutgens2, R. Urbanus6, J. Faber1

  • Abstract Number: VPB0964

    Homocysteine as an independent thrombosis risk factor

    G. Sottilotta1, G. Nicolò2

  • Abstract Number: OC 69.3

    Homology Directed Repair Edited Megakaryocytes For Rapid Screening of Platelet Gene Variant Functions

    Y. Kosaka1, S. Jacob1, E. Montenont1, J. Rowley2

  • Abstract Number: VPB1426

    How can changes in secondary haemostasis be useful for the management of pregnancy ?

    L. Stanciakova1, M. Dobrotova2, P. Holly3, J. Zolkova2, L. Vadelova4, I. Skornova2, J. Ivankova3, M. Brunclikova2, M. Samos5, T. Bolek5, M. Grendar6, P. Kubisz2, J. Stasko2

  • Abstract Number: PB0814

    How do laboratories perform von Willebrand disease (VWD) diagnostics?

    M. Hollestelle1, J. Meijers2, J. Eikenboom3, P. Meijer1

  • Abstract Number: PB0391

    Human platelets do not express a functional FcERI receptor on their surface

    C. TACQUARD1, F. TUPIN2, S. MAGNENAT3, C. METZ-FAVRE4, P. MERTES5, C. GACHET3, B. HECHLER3

  • Abstract Number: OC 36.2

    Hydrophobic patch (PLVIVG 1481-1486) in FV-Short crucial for its synergistic TFPI-cofactor activity with protein S and the formation of a FXa-inhibitory complex comprising FV-Short, protein S and TFPI

    B. Dahlback, S. Tran

  • Abstract Number: PB0411

    Hydroxychloroquine as an adjunct treatment for patients with triple positive thrombotic antiphospholipid syndrome- a single centre experience

    C. Crossette-Thambiah1, M. Laffan2, D. Arachchillage3

  • Abstract Number: VPB1424

    Hypercoagulability and Inflammatory Markers in a Case of Congenital TTP Complicated by Fetal Demise

    L. Skeith1, K. Hurd1, L. Almeida1, A. Dufour1, A. Lee2, D. Goodyear1, L. Girard1, J. Soucie1, J. Nicholas1, P. Schneider1, E. Agbani3

  • Abstract Number: PB0594

    Hypercoagulability in COVID-19 and its putative association with the downregulation of protein C signalling

    B. dos Santos Silva1, C. Jara2, D. Sidarta-Oliveira3, L. Velloso3, W. Velander2, E. P Araujo3

  • Abstract Number: PB0060

    Hypercoagulability in COVID-19: Is there an Antiphospholipid Syndrome?

    K. Bliden1, A. Sadeghi-Khomami2, K. Dier3, P. kundan1, U. Tantry4, Y. Alasadi5, P. Gurbel6

  • Abstract Number: VPB0491

    Hyperfibrinolysis Drives Instabilities in Trauma Induced Coagulopathy

    A. Gosselin1, V. Tutwiler2

  • Abstract Number: PB1226

    Hyperglycaemia enhances platelet degranulation and microparticle shedding: a novel mechanism underlying thrombotic complications in diabetes patients.

    N. Wolska1, R. Haghiri Limoudehi1, M. Kuhr2, G. Pula2

  • Abstract Number: OC 33.2

    Hyperinflammatory state and death in patients affected by COVID-19: role of vaccines.

    L. Marchini, M. Vedovati, C. Becattini

  • Abstract Number: PB0087

    Hyperresponsive platelets and a reduced platelet granule release capacity is associated with severity of COVID-19 symptoms and with increased mortality.

    F. Garishah1, D. Huskens2, S. Pramudo3, D. Andriani4, m. Astrilia5, R. Sentosa6, A. van der Ven1, B. de Laat7, M. Gasem6, Q. de Mast8, M. Roest9

  • Abstract Number: PB0627

    Hypofibrinolysis in patients with aortic stenosis is driven by overexpression of plasminogen activator inhibitor type 1 (PAI- 1) associated with elevated oxidized lipoproteins

    M. Kopytek1, A. Undas2, M. Ząbczyk2, J. Natorska2

  • Abstract Number: PB0555

    Hypoplasminogenemia: an International retroSpecTive and prOspective cohoRt studY (HISTORY): the international registry of patients with plasminogen deficiency

    M. Menegatti1, J. Bowen2, M. Boscarino1, C. Nakar2, R. Palla3, S. Siboni4, M. Torres5, M. Batur6, R. Natesirinilkul7, C. Roberson2, H. McDaniel8, S. Al9, N. Rodriguez10, T. Celkan11, J. Ceresetto12, N. Thukral2, B. Hardesty2, F. Peyvandi13, A. Shapiro14

  • Abstract Number: PB1041

    Hypoxia increases coagulation which is more pronounced in women but is counterbalanced by a decreased platelet reactivity

    M. Ninivaggi1, H. Middelveld2, V. Schmalschläger3, M. Roest1, R. de Laat-Kremers4, B. de Laat3

  • Abstract Number: OC 05.3

    Hypoxia promotes metabolic and functional platelet exhaustion in critically ill COVID-19 patients

    L. lombardi1, F. Maiorca2, R. Marrapodi1, N. Scafa3, S. Cesaroni4, B. Corica4, G. Romiti4, P. Pasculli4, M. Ciardi1, F. Ruberto5, F. Pugliese6, F. Pulcinelli1, C. Mastroianni1, S. Basili4, L. Stefanini1

Jump to:  View All • a b c d e f g [h] i j k l m n o p q r s t u v w x y z
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2022 John Wiley & Sons, Inc. All Rights Reserved.
Wiley